Abstract
Glioblastoma Multiforme (GBM) tumors are the most common type of brain tumors. These tumors are in general very malignant and can be characterized as rapidly progressive astrocytomas. The pathological characteristics of these tumors are exemplified by an active invasiveness, necrosis and a specialized form of angiogenesis, known as microvascular hyperplasia. These pathological features are thought to be due to tissue hypoxia. Cells that are under hypoxic stress can either develop an adaptive response that includes increasing the rate of glycolysis and angiogenesis or undergo cell death by promoting apoptosis and/or necrosis. The ability of tumor cells to maintain a balance between an adaptation to hypoxia and cell death is regulated by a family of transcription factors called hypoxia-inducing factors (HIF), which are essential for the regulation of the expression of a large number of hypoxia-responsive genes. The hypothesis that tumor hypoxia would facilitate the likelihood of metastases, tumor recurrence, resistance to chemotherapy and radiotherapy and the invasive potential; all of which culminate in a decrease in patient survival. In this review we will summarize the role of hypoxia in GBM with regard to drug therapy and toxicity and attempt to describe the possible interactions between hypoxia and apoptosis.
Current Molecular Pharmacology
Title: Hypoxia and the Malignant Glioma Microenvironment: Regulation and Implications for Therapy
Volume: 2
Author(s): L. Oliver, C. Olivier, F. B. Marhuenda, M. Campone and F. M. Vallette
Affiliation:
Keywords: Apoptosis, hypoxia, glioma
Abstract: Glioblastoma Multiforme (GBM) tumors are the most common type of brain tumors. These tumors are in general very malignant and can be characterized as rapidly progressive astrocytomas. The pathological characteristics of these tumors are exemplified by an active invasiveness, necrosis and a specialized form of angiogenesis, known as microvascular hyperplasia. These pathological features are thought to be due to tissue hypoxia. Cells that are under hypoxic stress can either develop an adaptive response that includes increasing the rate of glycolysis and angiogenesis or undergo cell death by promoting apoptosis and/or necrosis. The ability of tumor cells to maintain a balance between an adaptation to hypoxia and cell death is regulated by a family of transcription factors called hypoxia-inducing factors (HIF), which are essential for the regulation of the expression of a large number of hypoxia-responsive genes. The hypothesis that tumor hypoxia would facilitate the likelihood of metastases, tumor recurrence, resistance to chemotherapy and radiotherapy and the invasive potential; all of which culminate in a decrease in patient survival. In this review we will summarize the role of hypoxia in GBM with regard to drug therapy and toxicity and attempt to describe the possible interactions between hypoxia and apoptosis.
Export Options
About this article
Cite this article as:
Oliver L., Olivier C., Marhuenda B. F., Campone M. and Vallette M. F., Hypoxia and the Malignant Glioma Microenvironment: Regulation and Implications for Therapy, Current Molecular Pharmacology 2009; 2 (3) . https://dx.doi.org/10.2174/1874467210902030263
DOI https://dx.doi.org/10.2174/1874467210902030263 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
An Overview of Targeted Alpha Therapy with <sup>225</sup>Actinium and <sup>213</sup>Bismuth
Current Radiopharmaceuticals Intracellular Bioinorganic Chemistry and Cross Talk Among Different -Omics
Current Topics in Medicinal Chemistry Targeting the Perpetrator: Breast Cancer Stem Cell Therapeutics
Current Drug Targets PI3K/ Akt/ mTOR Pathway as a Therapeutic Target for Colorectal Cancer: A Review of Preclinical and Clinical Evidence
Current Drug Targets Quinazolines as Apoptosis Inducers and Inhibitors: A Review of Patent Literature
Recent Patents on Anti-Cancer Drug Discovery Receptor-Specific Peptides for Targeting of Liposomal, Polymeric, and Dendrimeric Nanoparticles in Cancer Diagnosis and Therapy
Current Molecular Imaging (Discontinued) Inflammation and Cancer: In Medio Stat Nano
Current Medicinal Chemistry DLX6-AS1: An Indispensable Cancer-related Long Non-coding RNA
Current Pharmaceutical Design The Microarray Gene Profiling Analysis of Glioblastoma Cancer Cells Reveals Genes Affected by FAK Inhibitor Y15 and Combination of Y15 and Temozolomide
Anti-Cancer Agents in Medicinal Chemistry Recent Developments in the Chemical Biology of Epothilones
Current Pharmaceutical Design Apoptosis Signaling Pathways in Anticancer Therapy
Current Cancer Therapy Reviews Neuroprotection by Estrogen and Progesterone in Traumatic Brain Injury and Spinal Cord Injury
Current Neuropharmacology Brain Endothelial Cell-Cell Junctions: How to “Open” the Blood Brain Barrier
Current Neuropharmacology Growth Retardation of Poorly Transfectable Tumor by Multiple Injections of Plasmids Encoding PE40 Based Targeted Toxin Complexed with Polyethylenimine
Current Gene Therapy Plants vs. Cancer: A Review on Natural Phytochemicals in Preventing and Treating Cancers and Their Druggability
Anti-Cancer Agents in Medicinal Chemistry The Disposal of Reactive Carbonyl Species through Carnosine Conjugation: What We Know Now
Current Medicinal Chemistry How do Glial Cells Contribute to Motor Control?
Current Pharmaceutical Design A Review on Recent Developments in the Anticancer Potential of Oleanolic Acid and its Analogs (2017-2020)
Mini-Reviews in Medicinal Chemistry Novel Therapeutic Targets in Neuropsychiatric Disorders: The Neuroepigenome
Current Pharmaceutical Design The Urokinase-type Plasminogen Activator and the Generation of Inhibitors of Urokinase Activity and Signaling
Current Pharmaceutical Design